These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

763 related items for PubMed ID: 18060931

  • 1. Combining neuroendocrine inhibitors in heart failure: reflections on safety and efficacy.
    Jneid H, Moukarbel GV, Dawson B, Hajjar RJ, Francis GS.
    Am J Med; 2007 Dec; 120(12):1090.e1-8. PubMed ID: 18060931
    [Abstract] [Full Text] [Related]

  • 2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 3. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
    McMurray JJ, Pfeffer MA, Swedberg K, Dzau VJ.
    Circulation; 2004 Nov 16; 110(20):3281-8. PubMed ID: 15545527
    [No Abstract] [Full Text] [Related]

  • 4. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: choice of agents and clinical impact.
    Jorde UP.
    Cardiol Rev; 2006 Nov 16; 14(2):81-7. PubMed ID: 16493245
    [Abstract] [Full Text] [Related]

  • 5. Should angiotensin receptor blockers be added to angiotensin-converting enzyme inhibitors in the treatment of heart failure?
    Ghanem FA, Movahed A.
    Rev Cardiovasc Med; 2005 Nov 16; 6(4):206-13. PubMed ID: 16379016
    [Abstract] [Full Text] [Related]

  • 6. [Hyperkalemia, heart failure and reduced renal function].
    Bugge JF.
    Tidsskr Nor Laegeforen; 2010 Jul 01; 130(13):1354-5. PubMed ID: 20596118
    [No Abstract] [Full Text] [Related]

  • 7. Pharmacotherapy for heart failure with left ventricular dysfunction: beyond angiotensin-converting enzyme inhibitors and beta-blockers.
    Norgard NB, Stark JE.
    Pharmacotherapy; 2008 Jul 01; 28(7):920-31. PubMed ID: 18576907
    [Abstract] [Full Text] [Related]

  • 8. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction.
    Azadpour M, Lamas GA.
    Expert Rev Cardiovasc Ther; 2004 Nov 01; 2(6):891-902. PubMed ID: 15500434
    [Abstract] [Full Text] [Related]

  • 9. [Treatment of heart failure based on large-scale clinical trials: renin-angiotensin system antagonists and beta-blockers].
    Kubota T, Takeshita A.
    Nihon Rinsho; 2003 May 01; 61(5):801-6. PubMed ID: 12755006
    [Abstract] [Full Text] [Related]

  • 10. Lack of deleterious interaction between angiotensin receptor blockers and beta-blockers in the treatment of patients with heart failure.
    Hennekens CH, Kowalczykowski M, Hollar D.
    J Cardiovasc Pharmacol Ther; 2006 Jun 01; 11(2):149-52. PubMed ID: 16891293
    [Abstract] [Full Text] [Related]

  • 11. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure.
    Bauersachs J, Fraccarollo D.
    Minerva Cardioangiol; 2003 Apr 01; 51(2):155-64. PubMed ID: 12783071
    [Abstract] [Full Text] [Related]

  • 12. Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure: an observational study of treatment rates and clinical outcome.
    Gotsman I, Rubonivich S, Azaz-Livshits T.
    Isr Med Assoc J; 2008 Mar 01; 10(3):214-8. PubMed ID: 18494235
    [Abstract] [Full Text] [Related]

  • 13. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials.
    Phillips CO, Kashani A, Ko DK, Francis G, Krumholz HM.
    Arch Intern Med; 2007 Oct 08; 167(18):1930-6. PubMed ID: 17923591
    [Abstract] [Full Text] [Related]

  • 14. Reassessing guidelines for heart failure.
    Drexler H, Wollert KC.
    J Renin Angiotensin Aldosterone Syst; 2004 Sep 08; 5 Suppl 1():S28-33. PubMed ID: 15526240
    [Abstract] [Full Text] [Related]

  • 15. Effects of ACE-inhibitors and beta-blockers on left ventricular remodeling in chronic heart failure.
    Khattar RS.
    Minerva Cardioangiol; 2003 Apr 08; 51(2):143-54. PubMed ID: 12783070
    [Abstract] [Full Text] [Related]

  • 16. Use of renin-angiotensin-aldosterone system inhibitors within the first eight to twelve weeks after renal transplantation.
    Jennings DL, Taber DJ.
    Ann Pharmacother; 2008 Jan 08; 42(1):116-20. PubMed ID: 18094340
    [Abstract] [Full Text] [Related]

  • 17. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM, Sanoski CA, Spinler SA.
    Pharmacotherapy; 2009 Jan 08; 29(1):31-48. PubMed ID: 19113795
    [Abstract] [Full Text] [Related]

  • 18. Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials.
    Tokmakova M, Solomon SD.
    Curr Opin Cardiol; 2006 Jul 08; 21(4):268-72. PubMed ID: 16755193
    [Abstract] [Full Text] [Related]

  • 19. Drug therapy of chronic heart failure in the elderly: the current state of clinical-trial evidence.
    Dulin BR, Krum H.
    Curr Opin Cardiol; 2006 Jul 08; 21(4):393-9. PubMed ID: 16755210
    [Abstract] [Full Text] [Related]

  • 20. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
    Saito M, Takada M, Hirooka K, Isobe F, Yasumura Y.
    J Clin Pharm Ther; 2005 Dec 08; 30(6):603-10. PubMed ID: 16336294
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.